Clareo Health | ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alnylam Pharmaceuticals
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented TTR mutation
Amyloid deposits in cardiac or non-cardiac tissue
Medical history of heart failure
Evidence of cardiac involvement by echocardiogram
You may not be if
Has known primary amyloidosis (AL), leptomeningeal amyloidosis, non-FAC hereditary cardiomyopathy, hypertensive cardiomyopathy, or cardiomyopathy due to valvular heart disease
Has known peripheral vascular disease affecting ambulation
Has a Polyneuropathy Disability score \>2
Has a New York Heart Association (NYHA) classification of IV
